Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Common Equity (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Common Equity for 15 consecutive years, with $14.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 53.84% to $14.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.2 million through Dec 2025, down 53.84% year-over-year, with the annual reading at $19.0 million for FY2025, 31.57% down from the prior year.
  • Common Equity for Q4 2025 was $14.2 million at Aytu Biopharma, down from $23.2 million in the prior quarter.
  • The five-year high for Common Equity was $137.6 million in Q2 2021, with the low at $14.2 million in Q4 2025.
  • Average Common Equity over 5 years is $47.9 million, with a median of $34.9 million recorded in 2025.
  • The sharpest move saw Common Equity surged 11149900.0% in 2021, then plummeted 67.79% in 2022.
  • Over 5 years, Common Equity stood at $105.5 million in 2021, then tumbled by 56.59% to $45.8 million in 2022, then decreased by 28.3% to $32.9 million in 2023, then decreased by 6.36% to $30.8 million in 2024, then tumbled by 53.84% to $14.2 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $14.2 million, $23.2 million, and $19.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.